What guidance did Legend Biotech's management provide for the next earnings period?

What were the key takeaways from Legend Biotech's earnings call?

What is Legend Biotech's gross profit margin?

What is Legend Biotech's latest dividend and current dividend yield?

What is the market's earnings forecast for Legend Biotech next quarter?

Did Legend Biotech beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Legend Biotech year over year?

What does Legend Biotech do and what are its main business segments?

- **CARVYKTI Growth Accelerates**: Q4 2025 sales $555M (+66% YoY), with 50.4-month PFS in triple-class exposed patients.
- **Profitability Milestone**: CARVYKTI franchise profitable in 2025; company-wide profitability expected in 2026.
- **Community Adoption Surge**: 1/3 U.S. treatment centers are regional hospitals, 50% doses administered outpatient.
- **Pipeline Momentum**: First in vivo CAR-T data expected in 2026; 1-2 U.S. IND filings planned.
- **Financial Strength**: $949M cash, 61% gross margin, operating loss narrowed 75% YoY.

**【CEO Summary Section】**
- CARVYKTI net trade sales reached $555 million in Q4 2025, up 66% YoY, with over 10,000 patients treated globally.
- Long-term data shows median PFS of 50.4 months for triple-class exposed patients, setting a new standard in multiple myeloma.
- 97% manufacturing success rate across 14 markets, with 294 global treatment sites.
- Company-wide profitability expected in 2026, supported by $949 million cash position.

**【Alan Bash (CARVYKTI President)】**
- U.S. net sales grew 38% YoY to $420 million, with 65% of patients in second to fourth line settings.
- Ex-U.S. sales tripled YoY to $135 million, driven by European expansion (Germany, Spain, Belgium).
- Global CARVYKTI adoption in community settings: 1/3 of U.S. treatment centers are regional hospitals, 50% doses administered in outpatient settings.

**【Carlos Santos (CFO)】**
- Q4 2025 revenue $306 million (+64% YoY), gross margin 61%, operating loss narrowed to -$20 million.
- CARVYKTI franchise profitable in 2025; enterprise-wide profitability on track for 2026.
- R&D expenses down 38% YoY, SG&A up 22% for commercial expansion.
- Adjusted net income $2.5 million vs. -$59 million YoY, cash balance $949 million.

**【Q&A Key Highlights】**
- **Growth Outlook**: 50%+ CARVYKTI sales growth in 2026, driven by earlier line adoption (currently <5% penetration in second to fourth line).
- **Business Development**: Seeking in vivo CAR-T partners for global development; no interest in Tec-Dara-related assets.
- **Manufacturing Scale**: 10,000 annual doses capacity achieved, 20,000+ doses target by end-2026.
- **Community Expansion**: 80% U.S. myeloma patients live within 50 miles of a CARVYKTI site; 75% of Spanish patients treated in second/third line.
- **Competitive Dynamics**: FDA's non-priority review of anito-cel validates CARVYKTI's clinical differentiation.


Legend Biotech Corporation (LEGN) Q4 2025 Earnings Call Transcript

- **Revenue Growth**: CARVYKTI net sales up 84% YoY to $524M, with U.S. sales growing 53% YoY. 9,000+ patients treated globally.
- **Landmark Survival Data**: 1/3 of CARTITUDE-1 patients progression-free for 5+ years, first CAR-T with FDA-approved OS benefit.
- **Profitability Path**: CARVYKTI to reach profitability in 2025, company-wide in 2026 with $1B cash runway.
- **Capacity Expansion**: 10,000+ annual doses by 2026, 132 U.S. sites (1/3 in community), 246 global sites.
- **Innovation Pipeline**: CARTITUDE-10 fludarabine-free trial underway; LUCAR-G39D shows promise in NHL.

**【CEO Summary Section】**
- CARVYKTI net trade sales reached $524 million in Q3 2025, up 84% year-over-year, with U.S. sales growing 53% YoY and 11% QoQ. Over 9,000 patients have been treated globally.
- CARTITUDE-1 trial showed 1/3 of patients remained progression-free and off therapy for 5+ years, marking a potential 'cure' milestone. FDA updated label to include overall survival benefit from CARTITUDE-4.
- CARTITUDE-10 trial initiated to evaluate fludarabine-free lymphodepletion regimen. ASH 2025 will feature data on CARVYKTI's durability in standard-risk myeloma and immune biomarkers.
- Global manufacturing capacity expanded to 10,000 annualized doses, with Tech Lane facility now in commercial production.

**【CFO Financial Commentary】**
- Total revenue $272 million (84% YoY growth), driven by CARVYKTI net sales and collaboration revenue. Adjusted net loss $19 million (vs. $38 million YoY), with operating loss down 38% to $43 million.
- Gross margin stable at 57%. R&D/S&M expenses declining as a percentage of revenue (42%/32%).
- Cash position $1 billion, with $29 million cash flow from operations. Anticipate CARVYKTI profitability by end-2025 and company-wide profitability in 2026.

**【Q&A Highlights】**
- **Capacity & Utilization**: 10,000+ annual doses achievable in 2026, with Raritan expansion on track for FDA approval by year-end. 132 U.S. sites (1/3 in community settings), 246 global sites.
- **Community Growth**: 60% of U.S. scripts from second-fourth line, fastest growth in third line. Outpatient administration now 50% of patients.
- **Competitive Strategy**: CARTITUDE-10 data could support label expansion. MRD as surrogate endpoint under FDA discussion.
- **Pipeline**: LUCAR-G39D allogeneic CAR-T shows encouraging efficacy in NHL. New R&D facility focuses on in vivo delivery innovation.

Legend Biotech Corporation (LEGN) Q3 2025 Earnings Call Transcript

- **Record Sales Growth**: CARVYKTI Q2 sales of $439 million (+136% YoY), driven by 60% utilization in earlier lines and 59% OUS growth.
- **Breakthrough Survival Data**: 1/3 of CARTITUDE-1 patients remain progression-free at 5+ years, with 37-month PFS in high-risk cytogenetics.
- **Operational Efficiency**: $22 million Q2 operating loss (down 47% YoY), 57% gross margin, and $1 billion cash runway.
- **Strategic Expansion**: 123 U.S. treatment sites, 213 global sites, and 50%+ community oncology penetration.
- **Pipeline Momentum**: LB1908/LB2102 Phase I success, TaVec platform advancement, and CARTITUDE-6 enrollment completion.

**【CEO Summary Section】**
- CARVYKTI net trade sales reached $439 million in Q2 2025, up 136% year-over-year, with over 7,500 patients treated globally.
- Regulatory updates include FDA REMS removal, reducing post-treatment monitoring from 4 weeks to 2 weeks and driving patient access.
- Pipeline progress: LB1908 and LB2102 show promising safety and efficacy in Phase I studies; TaVec platform for off-the-shelf therapies is advancing.
- Long-term survival data from CARTITUDE-1 shows 1/3 of patients remain progression-free at 5+ years, setting a new benchmark in multiple myeloma.
- Targeting operational breakeven for CARVYKTI by end-2025 and company-wide profitability in 2026.

**【CFO Financial Commentary】**
- Q2 2025 total revenues: $255 million (136% YoY growth), with $125 million net loss and $10 million adjusted net income.
- Operating loss improved to $22 million (down 47% YoY), driven by gross margin of 57% and disciplined expense management.
- $1 billion cash position supports R&D, manufacturing expansion, and community outreach.

**【Q&A Key Highlights】**
- **CARVYKTI Expansion**: 123 U.S. treatment sites (70% in community settings), 213 global sites, and 59% QoQ growth in OUS sales ($81 million).
- **Safety & Efficacy**: Blood paper shows 0% delayed neurotoxicity in 98 patients with TALVEY bridging, vs. 2% in competing datasets.
- **Pipeline Updates**: CARTITUDE-6 enrollment complete; CARTITUDE-5 interim data pending event-driven analysis.
- **Community Strategy**: Virginia Oncology Associates (VOA) partnership exemplifies direct-to-patient engagement, with 30% U.S. patients now in earlier lines.
- **Tariff Impact**: Minimal exposure due to U.S.-based manufacturing.


Legend Biotech Corporation (LEGN) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 CARVYKTI sales up 135% YoY to $369M, with 6,000+ patients treated globally.
- **Early-Line Penetration**: 55% of U.S. community oncologists prefer CARVYKTI in early-line myeloma (vs. 34% pre-CARTITUDE-4 data).
- **Operational Efficiency**: 97% manufacturing success, 30-day median turnaround, 95% on-time delivery.
- **Pipeline Momentum**: In vivo CAR-T first patient dosing Q3 2025; DLL3 and Claudin 18.2 Phase 1 data at ASCO 2025.
- **Profitability Path**: $1B cash runway supports 2026 profitability (excluding FX); 2025 breakeven for CARVYKTI.


**【CEO Summary Section】**
- CARVYKTI net trade sales reached $369 million, a 135% YoY increase, with over 6,000 patients treated globally.
- U.S. utilization in early-line settings exceeds 50%, driven by CARTITUDE-4 data showing 55% physician preference for CARVYKTI in early-line multiple myeloma.
- Europe expanded with approvals in Australia and Spain, targeting 10,000 annualized patient doses by end-2025.
- In vivo CAR-T platform investment includes a new Philadelphia facility, aiming for first patient dosing in Q3 2025.

**【CFO Financial Commentary】**
- Q1 2025 total revenues $195 million, with collaboration revenue up 137% YoY.
- Adjusted net loss $27 million (excluding $52 million FX loss), operating loss reduced 56% YoY to $51 million.
- Gross margin improved to 63% (Q4 2024: 59%), R&D/Sales & Admin expenses tightly controlled.
- $1 billion cash position supports 2026 profitability target (excluding FX fluctuations).

**【Q&A Key Highlights】**
- **Community Penetration**: 70% of community oncologists aware of CARVYKTI; 60% of Q1 patients from CARTITUDE-4 population, expected to rise to 75% by end-2025.
- **Manufacturing Efficiency**: 97% manufacturing success rate, 30-day median turnaround time, 95% on-time delivery.
- **Pipeline Progress**: In vivo CAR-T first patient dosing in Q3 2025; DLL3 and Claudin 18.2 Phase 1 data at ASCO 2025.
- **Regulatory Updates**: U.S. label expansion for overall survival expected Q4 2025; Europe added OS to label post-CHMP approval.
- **Partnership Dynamics**: J&J/CB30 pathway for Raritan expansion on track for H2 2025 approval; $150M joint Tech Lane Phase 2 investment.


Legend Biotech (LEGN)-13 May 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: Q4 2024 CARVYKTI sales $334M (+110% YoY), 60% in second-line use vs prior line. 
- **Outpatient Expansion**: >50% treatments now outpatient, targeting 100% by end-2025. 
- **Pipeline Momentum**: DLL-3 and Claudin18.2 CAR-Ts in Phase 1, autoimmune program in 10+ indications. 
- **2025 Goals**: Double supply to 10,000 doses, achieve operational breakeven, $1.1B cash runway to 2026 profitability. 
- **Safety Innovation**: ALC biomarker monitoring for neurotoxicity mitigation in 20% of patients. 


**【CEO Opening Remarks】**
- CARVYKTI Q4 net trade sales: $334M (110% YoY growth, 17% QoQ growth). US sales dominate at 91%, OUS sales $31M (138% YoY growth). 
- 102 US hospitals certified for CARVYKTI treatment, 50%+ administered in outpatient settings. 
- 2025 goals: Double CARVYKTI supply to 10,000 doses, achieve operational breakeven, expand pipeline into solid tumors and autoimmune diseases. 
- Key clinical milestone: CARTITUDE-4 Phase 3 study shows 89% MRD negativity vs 38% standard of care at 3-year follow-up. 

**【CFO Financial Highlights】
- Q4 2024 total revenue: $187M (collaboration revenue $168M, license revenue $18M). 
- Net profit: $26M ($0.07 EPS) vs $145M loss (-$0.40 EPS) prior year, driven by $110M unrealized FX gain. 
- Key expenses: 
  - Collaboration COGS: $69M (vs $32M prior year) 
  - R&D: $104M (flat vs prior year) 
  - SG&A: $49M (15% YoY growth for commercial expansion) 
- Cash balance: $1.1B, sufficient to fund operations until 2026 profitability. 

**【Q&A Key Takeaways】
1. **Safety & Mitigation**
- CARTITUDE trials now include ALC biomarker monitoring (threshold 3,000 cells/µL) with dexamethasone prophylaxis for neurotoxicity. 20% of patients may benefit. 
- Outpatient administration now >50% of cases, targeting 100% by end-2025. 

2. **Market Demand & Competition**
- 60% of Q4 usage in second-line (2-4) vs prior line, IMWG guidelines recommend CAR-T first. 
- 2026 capacity of 10,000 doses vs 4,000 in 2024, supply will outpace demand. 
- Leading 90%+ market share in multiple myeloma CAR-T, no near-term competitor approvals expected. 

3. **Pipeline Progress**
- Solid tumor programs: DLL-3 (small cell lung cancer) and Claudin18.2 (gastric cancer) in Phase 1. 
- Autoimmune program targeting CD19/20/22 in >10 indications. 
- New R&D facility in Philadelphia opening Q2 2025. 

4. **Financial Outlook**
- 2025 revenue growth driven by US expansion (102 hospitals), Europe (Germany, Austria, Spain reimbursement), and Belgium manufacturing ramp. 
- 2026 profitability target excludes FX gains/losses, supported by $1.1B cash balance. 


Actual	-0.63	-0.25	-0.22	-0.3	-0.33	-0.43	-0.3	-0.13	-0.35	-0.37	-0.32	-0.34	-0.57	-0.17	-0.4	-0.16	-0.05	-0.34	0.07	-0.27	-0.34	-0.11	-0.08
Forecast	-0.26	-0.3067	-0.2833	-0.35	-0.335	-0.4156	-0.3418	-0.3583	-0.3102	-0.3733	-0.3831	-0.4175	-0.3609	-0.3101	-0.3556	-0.1935	-0.2874	-0.3297	-0.2474	-0.2104	-0.1135	-0.0727	0.0005
Surprise	-142.31%	+18.49%	+22.34%	+14.29%	+1.49%	-3.46%	+12.23%	+63.72%	-12.83%	+0.88%	+16.47%	+18.56%	-57.94%	+45.18%	-12.49%	+17.31%	+82.60%	-3.12%	+128.29%	-28.33%	-199.56%	-51.31%	-16100.00%

LEGN

LEGN fundamentals

LEGN Q4 2025 Earnings

Earnings Call

You can ask Aime

LEGN

LEGN fundamentals

LEGN Q4 2025 Earnings

Earnings Call

LEGN Earnings Call Summary for Q4/20258:00 AM on Mar 10, 2026

LEGN Earnings Call Summary for Q3/20258:00 AM on Nov 12, 2025

LEGN Earnings Call Summary for Q2/20258:00 AM on Aug 11, 2025

LEGN Earnings Call Summary for Q1/20258:00 AM on May 13, 2025

LEGN Earnings Call Summary for Q4/20248:00 AM on Mar 11, 2025

You can ask Aime